WO2012032519A3 - Méthodes de diagnostic de la maladie de parkinson - Google Patents

Méthodes de diagnostic de la maladie de parkinson Download PDF

Info

Publication number
WO2012032519A3
WO2012032519A3 PCT/IL2011/000720 IL2011000720W WO2012032519A3 WO 2012032519 A3 WO2012032519 A3 WO 2012032519A3 IL 2011000720 W IL2011000720 W IL 2011000720W WO 2012032519 A3 WO2012032519 A3 WO 2012032519A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
genes
methods
subject
parkinson
Prior art date
Application number
PCT/IL2011/000720
Other languages
English (en)
Other versions
WO2012032519A2 (fr
Inventor
Hermona Soreq
Hagai Bergman
David S. Greenberg
Zvi Israel
Lilach Soreq
Original Assignee
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
Hadasit Medical Research Services And Development Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd., Hadasit Medical Research Services And Development Ltd. filed Critical Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
Publication of WO2012032519A2 publication Critical patent/WO2012032519A2/fr
Publication of WO2012032519A3 publication Critical patent/WO2012032519A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Developmental Disabilities (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode visant à diagnostiquer la maladie de Parkinson chez un sujet. La méthode consiste à déterminer un taux d'expression d'une pluralité de gènes dans un échantillon prélevé chez le sujet, la pluralité de gènes comprenant PJA1, TRAM1, PTPN1, PCBP2, NR2F1 et HNRPDL. Une différence importante d'un point de vue statistique entre les taux d'expression de la pluralité de gènes dans l'échantillon prélevé chez le sujet et les taux d'expression de la pluralité de gènes dans un échantillon témoin indique que le sujet est atteint de la maladie de Parkinson.
PCT/IL2011/000720 2010-09-07 2011-09-07 Méthodes de diagnostic de la maladie de parkinson WO2012032519A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38036010P 2010-09-07 2010-09-07
US61/380,360 2010-09-07

Publications (2)

Publication Number Publication Date
WO2012032519A2 WO2012032519A2 (fr) 2012-03-15
WO2012032519A3 true WO2012032519A3 (fr) 2012-07-05

Family

ID=44898119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2011/000720 WO2012032519A2 (fr) 2010-09-07 2011-09-07 Méthodes de diagnostic de la maladie de parkinson

Country Status (1)

Country Link
WO (1) WO2012032519A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106021915B (zh) * 2016-05-17 2021-04-13 华南师范大学 基于大数据面向自动诊疗的医疗数据分析系统和装置

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180807B2 (en) * 2011-11-04 2021-11-23 Population Bio, Inc. Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
CN104479027B (zh) * 2014-11-20 2017-06-16 华中科技大学 一种防治老年痴呆的药物
EP3091087A1 (fr) * 2015-05-08 2016-11-09 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Procédé de diagnostic in vitro de synucléinopathies utilisant des transcriptions du gène de l'alpha-synucléine
SG11201906947SA (en) 2017-02-17 2019-08-27 Bristol Myers Squibb Co Antibodies to alpha-synuclein and uses thereof
CN109545370B (zh) * 2018-10-27 2023-08-22 平安医疗健康管理股份有限公司 基于样本处理的病种确定方法、装置及终端
CN115957349B (zh) * 2022-10-08 2024-04-05 华中农业大学 激活猪的pja1基因表达的制剂在制备猪抗猪流行性腹泻病毒感染药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050475A2 (fr) * 2004-11-03 2006-05-11 Brigham And Women's Hospital, Inc. Identification de genes deregules chez des patients presentant des maladies neurologiques

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
KR100236506B1 (ko) 1990-11-29 2000-01-15 퍼킨-엘머시터스인스트루먼츠 폴리머라제 연쇄 반응 수행 장치
CA2218875C (fr) 1991-07-23 2000-11-07 The Research Foundation Of State University Of New York Ameliorations de la pcr in situ
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5612473A (en) 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050475A2 (fr) * 2004-11-03 2006-05-11 Brigham And Women's Hospital, Inc. Identification de genes deregules chez des patients presentant des maladies neurologiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Parkinson's Disease: Hope Through Research.", NIH PUBLICATIONS, no. 06-139, 1 January 2006 (2006-01-01), Bethesda MD USA, pages 1 - 20, XP002666546, Retrieved from the Internet <URL:http://www.ninds.nih.gov/disorders/parkinsons_disease/detail_parkinsons_disease.htm> [retrieved on 20120103] *
BARDIEN S ET AL: "Molecular analysis of the parkin gene in South African patients diagnosed with Parkinson's disease", PARKINSONISM AND RELATED DISORDERS, ELSEVIER SCIENCE, OXFORD, GB, vol. 15, no. 2, 1 February 2009 (2009-02-01), pages 116 - 121, XP025895201, ISSN: 1353-8020, [retrieved on 20080602], DOI: 10.1016/J.PARKRELDIS.2008.04.005 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106021915B (zh) * 2016-05-17 2021-04-13 华南师范大学 基于大数据面向自动诊疗的医疗数据分析系统和装置

Also Published As

Publication number Publication date
WO2012032519A2 (fr) 2012-03-15

Similar Documents

Publication Publication Date Title
WO2012032519A3 (fr) Méthodes de diagnostic de la maladie de parkinson
WO2011135194A3 (fr) Procédé pour diagnostiquer un risque de diabète de type 1 et prévenir le déclenchement d&#39;un diabète de type 1
WO2013003350A3 (fr) Arnmi comme biomarqueurs indicateurs de la maladie d&#39;alzheimer
WO2013036929A8 (fr) Procédés permettant d&#39;obtenir une séquence
WO2010062960A3 (fr) Méthodes de détermination d&#39;une réceptivité à une thérapie par anti-tnfα lors d&#39;une maladie intestinale inflammatoire
WO2016015058A3 (fr) Procédés de détermination de types de tissus et/ou de cellules permettant d&#39;obtenir de l&#39;adn sans cellules, et procédés d&#39;identification d&#39;une maladie ou d&#39;un trouble les employant
WO2011015944A3 (fr) Utilisation d&#39;adn libre en tant que prédicteur précoce de la gravité d&#39;une pancréatite aiguë
WO2013113012A3 (fr) Procédés de profilage et de quantification d&#39;arn acellulaire
CA2840149C (fr) Methodes et acides nucleiques permettant d&#39;etablir le pronostic d&#39;un sujet atteint de cancer
WO2012104340A3 (fr) Marqueurs de mélanome et leurs utilisations
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
WO2014022826A3 (fr) Biomarqueur associé au risque de récurrence du mélanome
WO2011063098A3 (fr) Marqueurs génétiques pour la gestion du poids et procédés d&#39;utilisation de ceux-ci
WO2009036933A3 (fr) Régulation à la baisse de l&#39;expression génique à l&#39;aide de particules pseudovirales chargées d&#39;acide nucléique
WO2014060785A3 (fr) Procédé de diagnostic pour prédire une réponse à un inhibiteur de tnfα
WO2011106549A3 (fr) Procédés pour déterminer les interactions gène-nutriment
WO2008073921A3 (fr) Gènes et voies régulés par mir-126 comme cibles d&#39;intervention thérapeutique
WO2011133036A3 (fr) Moyens et méthodes de détermination du risque de maladie cardiovasculaire
WO2009149319A3 (fr) Profils d’expression de gène associés à des crises d’exacerbation d’asthme
WO2012056451A3 (fr) Marqueurs géniques du sang périphérique destinés au diagnostic précoce de la maladie de parkinson
WO2009076229A3 (fr) Procédés permettant de déterminer si un sujet réagira à un inhibiteur bcr-abl
WO2011100752A3 (fr) Procédés et matériaux pour l&#39;évaluation de l&#39;expression d&#39;arn
WO2010007083A3 (fr) Procédés et acides nucléiques pour l’analyse de troubles prolifératifs cellulaires
WO2009125303A3 (fr) Procédé et appareil de détermination d&#39;une probabilité de cancer colorectal chez un sujet
WO2012101219A3 (fr) Ensembles de miarn complexes en tant que nouveaux biomarqueurs pour des maladies pulmonaires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11770875

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11770875

Country of ref document: EP

Kind code of ref document: A2